176 related articles for article (PubMed ID: 20859651)
1. Liposomal cytarabine for central nervous system embryonal tumors in children and young adults.
Partap S; Murphy PA; Vogel H; Barnes PD; Edwards MS; Fisher PG
J Neurooncol; 2011 Jul; 103(3):561-6. PubMed ID: 20859651
[TBL] [Abstract][Full Text] [Related]
2. Safety and toxicity of intrathecal liposomal cytarabine (Depocyte) in children and adolescents with recurrent or refractory brain tumors: a multi-institutional retrospective study.
Benesch M; Siegler N; Hoff Kv; Lassay L; Kropshofer G; Müller H; Sommer C; Rutkowski S; Fleischhack G; Urban C
Anticancer Drugs; 2009 Oct; 20(9):794-9. PubMed ID: 19617818
[TBL] [Abstract][Full Text] [Related]
3. Toxicity and efficacy of intrathecal liposomal cytarabine in children with leukemia/lymphoma relapsing in the central nervous system: a retrospective multicenter study.
Parasole R; Petruzziello F; Messina C; Barisone E; Pession A; Locatelli F; Micalizzi C; Cesaro S; Testi AM; De Matteo A; Varotto S; Berger M; Morello W; Menna G; Poggi V
Leuk Lymphoma; 2015 Mar; 56(3):650-5. PubMed ID: 24882262
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and safety of intrathecal liposomal cytarabine in children aged <3 years.
Peyrl A; Sauermann R; Traunmueller F; Azizi AA; Gruber-Olipitz M; Gupper A; Slavc I
Clin Pharmacokinet; 2009; 48(4):265-71. PubMed ID: 19492871
[TBL] [Abstract][Full Text] [Related]
5. Liposomal cytarabine in the prophylaxis and treatment of CNS lymphoma: toxicity analysis in a retrospective case series study conducted at Polish Lymphoma Research Group Centers.
Jurczak W; Kroll-Balcerzak R; Giebel S; Machaczka M; Giza A; Ogórka T; Fornagiel S; Rybka J; Wróbel T; Kumiega B; Skotnicki AB; Komarnicki M
Med Oncol; 2015 Apr; 32(4):90. PubMed ID: 25716885
[TBL] [Abstract][Full Text] [Related]
6. [Liposomal cytarabine in prophylaxis of the central nervous system involvement in rare aggresive lymphomas].
Kumiega B; Jurczak W; Fornagiel S; Dzietczenia J; Skotnicki AB
Przegl Lek; 2013; 70(4):187-90. PubMed ID: 23991555
[TBL] [Abstract][Full Text] [Related]
7. Intrathecal liposomal cytarabine and leptomeningeal medulloblastoma relapse: a valuable therapeutic option.
Mastronuzzi A; Del Bufalo F; Iacono A; Secco DE; Serra A; Colafati GS; DE Ioris MA; Corsetti T
Anticancer Res; 2013 Aug; 33(8):3515-8. PubMed ID: 23898128
[TBL] [Abstract][Full Text] [Related]
8. Liposomal cytarabine is effective and tolerable in the treatment of central nervous system relapse of acute lymphoblastic leukemia and very aggressive lymphoma.
Gökbuget N; Hartog CM; Bassan R; Derigs HG; Dombret H; Greil R; Hernández-Rivas JM; Huguet F; Intermesoli T; Jourdan E; Junghanss C; Leimer L; Moreno MJ; Reichle A; Ribera J; Schmid M; Serve H; Stelljes M; Stuhlmann R; Hoelzer D;
Haematologica; 2011 Feb; 96(2):238-44. PubMed ID: 20952517
[TBL] [Abstract][Full Text] [Related]
9. Differentiation of Outcomes by Treatment Regimen and Histology in Central Nervous System Primary Embryonal Tumors.
Bhimani AD; Ryoo JS; Reddy AK; Denyer S; McGuire LS; Alonso M; Mehta AI
World Neurosurg; 2020 Sep; 141():e289-e306. PubMed ID: 32434022
[TBL] [Abstract][Full Text] [Related]
10. Safety and tolerability of intrathecal liposomal cytarabine as central nervous system prophylaxis in patients with acute lymphoblastic leukemia.
Valentin A; Troppan K; Pfeilstöcker M; Nösslinger T; Linkesch W; Neumeister P
Leuk Lymphoma; 2014 Aug; 55(8):1739-42. PubMed ID: 24138308
[TBL] [Abstract][Full Text] [Related]
11. Feasibility and toxicity of intrathecal liposomal cytarabine in 5 children and young adults with refractory neoplastic meningitis.
Benesch M; Sovinz P; Krammer B; Lackner H; Mann G; Schwinger W; Gadner H; Urban C
J Pediatr Hematol Oncol; 2007 Apr; 29(4):222-6. PubMed ID: 17414563
[TBL] [Abstract][Full Text] [Related]
12. [Liposomal cytarabine for the treatment of leptomeningeal dissemination of central nervous system tumours in children and adolescents].
Moreno L; García Ariza MA; Cruz O; Calvo C; Fuster JL; Salinas JA; Moscardo C; Portugal R; Merino JM; Madero L
An Pediatr (Barc); 2016 Nov; 85(5):274.e1-274.e8. PubMed ID: 27086069
[TBL] [Abstract][Full Text] [Related]
13. Antiangiogenic metronomic therapy for children with recurrent embryonal brain tumors.
Peyrl A; Chocholous M; Kieran MW; Azizi AA; Prucker C; Czech T; Dieckmann K; Schmook MT; Haberler C; Leiss U; Slavc I
Pediatr Blood Cancer; 2012 Sep; 59(3):511-7. PubMed ID: 22147459
[TBL] [Abstract][Full Text] [Related]
14. Relapse patterns in pediatric embryonal central nervous system tumors.
Perreault S; Lober RM; Carret AS; Zhang G; Hershon L; Décarie JC; Yeom K; Vogel H; Fisher PG; Partap S
J Neurooncol; 2013 Nov; 115(2):209-15. PubMed ID: 23921420
[TBL] [Abstract][Full Text] [Related]
15. Intrathecal liposomal cytarabine in children under 4 years with malignant brain tumors.
Lassaletta A; Lopez-Ibor B; Mateos E; Gonzalez-Vicent M; Perez-Martinez A; Sevilla J; Diaz MA; Madero L
J Neurooncol; 2009 Oct; 95(1):65-69. PubMed ID: 19381444
[TBL] [Abstract][Full Text] [Related]
16. Embryonal Tumors of the Central Nervous System with Multilayered Rosettes and Atypical Teratoid/Rhabdoid Tumors.
Kamenova M; Kaneva R; Genova K; Gabrovsky N
Adv Exp Med Biol; 2023; 1405():225-252. PubMed ID: 37452940
[TBL] [Abstract][Full Text] [Related]
17. Treatment outcomes and late toxicities in patients with embryonal central nervous system tumors.
Odagiri K; Omura M; Hata M; Aida N; Niwa T; Goto H; Ito S; Adachi M; Yoshida H; Yuki H; Inoue T
Radiat Oncol; 2014 Sep; 9():201. PubMed ID: 25209395
[TBL] [Abstract][Full Text] [Related]
18. Phase I trial of intrathecal liposomal cytarabine in children with neoplastic meningitis.
Bomgaars L; Geyer JR; Franklin J; Dahl G; Park J; Winick NJ; Klenke R; Berg SL; Blaney SM
J Clin Oncol; 2004 Oct; 22(19):3916-21. PubMed ID: 15459213
[TBL] [Abstract][Full Text] [Related]
19. Central nervous system prophylaxis with intrathecal liposomal cytarabine in a subset of high-risk patients with diffuse large B-cell lymphoma receiving first line systemic therapy in a prospective trial.
González-Barca E; Canales M; Salar A; Ferreiro-Martínez JJ; Ferrer-Bordes S; García-Marco JA; Sánchez-Blanco JJ; García-Frade J; Peñalver J; Bello-López JL; Sancho JM; Caballero D;
Ann Hematol; 2016 May; 95(6):893-9. PubMed ID: 27025508
[TBL] [Abstract][Full Text] [Related]
20. Activity of postoperative carboplatin, etoposide, and high-dose methotrexate in pediatric CNS embryonal tumors: results of a phase II study in newly diagnosed children.
Kellie SJ; Wong CK; Pozza LD; Waters KD; Lockwood L; Mauger DC; White L
Med Pediatr Oncol; 2002 Sep; 39(3):168-74. PubMed ID: 12210445
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
